Optimizing Weight Loss Maintenance: Can Continuous Glucose Monitoring Play a Role (OWL-CGM)? A Randomized Controlled Feasibility Trial.

Clin NutrJul 21, 2026 (epub)
Clinical ResearchEndocrinology

Nurul Zafirah Mohd Hatta, Cindy M Gray, Michelle Harvie et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed the feasibility of continuous glucose monitoring (CGM) in a personalized weight loss maintenance program among adults who had lost over 5 kg. The study found that participants using CGM experienced a significant weight loss of -2.7 ± 1.1 kg compared to +0.5 ± 0.8 kg in the control group over 24 weeks (p = 0.032).

Key findings

  • Participants using CGM lost -2.7 ± 1.1 kg compared to +0.5 ± 0.8 kg in the PWM group (p = 0.032).
  • CGM users had a greater reduction in energy intake of -235.0 ± 123.0 kcal.day -1 versus +23.3 ± 201.6 kcal.day -1 (p = 0.007).
  • 83.7% of randomized participants completed the study, with high adherence to dietitian consultations and CGM usage.

Why it matters

Weight loss maintenance is a significant challenge for many individuals. This study suggests that CGM may enhance dietary adherence and weight management, potentially offering a valuable tool for clinicians in obesity management.

Source

PubMed · PMID 42541977

Published in Clin Nutr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.